WEDGE STEPHEN ROBERT
No ORCID on file
· 53 papers in corpus
2009
The combination of a VEGF receptor tyrosine kinase inhibitor with an inhibitor of the Src family of non-receptor tyrosine kinases can be used to produce a medicament for the substantially normotensive treatment of disease states associated …
2009
The combination of a VEGF receptor tyrosine kinase inhibitor with an inhibitor of the Src family of non-receptor tyrosine kinases can be used to produce a medicament for the substantially normotensive treatment of disease states associated …
2009
The combination of a VEGF receptor tyrosine kinase inhibitor with an inhibitor of the Src family of non-receptor tyrosine kinases can be used to produce a medicament for the substantially normotensive treatment of disease states associated …
2009
The combination of a VEGF receptor tyrosine kinase inhibitor with an inhibitor of the Src family of non-receptor tyrosine kinases can be used to produce a medicament for the substantially normotensive treatment of disease states associated …
2009
The combination of a VEGF receptor tyrosine kinase inhibitor with an inhibitor of the Src family of non-receptor tyrosine kinases can be used to produce a medicament for the substantially normotensive treatment of disease states associated …
2009
The combination of a VEGF receptor tyrosine kinase inhibitor with an inhibitor of the Src family of non-receptor tyrosine kinases can be used to produce a medicament for the substantially normotensive treatment of disease states associated …
2009
The combination of a VEGF receptor tyrosine kinase inhibitor with an inhibitor of the Src family of non-receptor tyrosine kinases can be used to produce a medicament for the substantially normotensive treatment of disease states associated …
2009
The combination of a VEGF receptor tyrosine kinase inhibitor with an inhibitor of the Src family of non-receptor tyrosine kinases can be used to produce a medicament for the substantially normotensive treatment of disease states associated …
2009
The combination of a VEGF receptor tyrosine kinase inhibitor with an inhibitor of the Src family of non-receptor tyrosine kinases can be used to produce a medicament for the substantially normotensive treatment of disease states associated …
2009
The combination of a VEGF receptor tyrosine kinase inhibitor with an inhibitor of the Src family of non-receptor tyrosine kinases can be used to produce a medicament for the substantially normotensive treatment of disease states associated …
2009
The combination of a VEGF receptor tyrosine kinase inhibitor with an inhibitor of the Src family of non-receptor tyrosine kinases can be used to produce a medicament for the substantially normotensive treatment of disease states associated …
2009
The combination of a VEGF receptor tyrosine kinase inhibitor with an inhibitor of the Src family of non-receptor tyrosine kinases can be used to produce a medicament for the substantially normotensive treatment of disease states associated …
2009
The combination of a VEGF receptor tyrosine kinase inhibitor with an inhibitor of the Src family of non-receptor tyrosine kinases can be used to produce a medicament for the substantially normotensive treatment of disease states associated …
2009
The combination of a VEGF receptor tyrosine kinase inhibitor with an inhibitor of the Src family of non-receptor tyrosine kinases can be used to produce a medicament for the substantially normotensive treatment of disease states associated …
2009
The combination of a VEGF receptor tyrosine kinase inhibitor with an inhibitor of the Src family of non-receptor tyrosine kinases can be used to produce a medicament for the substantially normotensive treatment of disease states associated …
2009
The combination of a VEGF receptor tyrosine kinase inhibitor with an inhibitor of the Src family of non-receptor tyrosine kinases can be used to produce a medicament for the substantially normotensive treatment of disease states associated …
2009
The combination of a VEGF receptor tyrosine kinase inhibitor with an inhibitor of the Src family of non-receptor tyrosine kinases can be used to produce a medicament for the substantially normotensive treatment of disease states associated …
2009
The combination of a VEGF receptor tyrosine kinase inhibitor with an inhibitor of the Src family of non-receptor tyrosine kinases can be used to produce a medicament for the substantially normotensive treatment of disease states associated …
2009
The combination of a VEGF receptor tyrosine kinase inhibitor with an inhibitor of the Src family of non-receptor tyrosine kinases can be used to produce a medicament for the substantially normotensive treatment of disease states associated …
2009
The combination of a VEGF receptor tyrosine kinase inhibitor with an inhibitor of the Src family of non-receptor tyrosine kinases can be used to produce a medicament for the substantially normotensive treatment of disease states associated …
2009
The combination of a VEGF receptor tyrosine kinase inhibitor with an inhibitor of the Src family of non-receptor tyrosine kinases can be used to produce a medicament for the substantially normotensive treatment of disease states associated …
2009
The combination of a VEGF receptor tyrosine kinase inhibitor with an inhibitor of the Src family of non-receptor tyrosine kinases can be used to produce a medicament for the substantially normotensive treatment of disease states associated …
2009
The combination of a VEGF receptor tyrosine kinase inhibitor with an inhibitor of the Src family of non-receptor tyrosine kinases can be used to produce a medicament for the substantially normotensive treatment of disease states associated …
2009
The combination of a VEGF receptor tyrosine kinase inhibitor with an inhibitor of the Src family of non-receptor tyrosine kinases can be used to produce a medicament for the substantially normotensive treatment of disease states associated …
2009
The combination of a VEGF receptor tyrosine kinase inhibitor with an inhibitor of the Src family of non-receptor tyrosine kinases can be used to produce a medicament for the substantially normotensive treatment of disease states associated …